Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-41557
Imhof, L; Goldinger, S M; Baumann, K; Schad, K; French, L E; Röthlisberger, P; Dummer, R (2011). The antibacterial substance, taurolidine in the second/third-line treatment of very advanced stage IV melanoma including brain metastases: results of a phase 2, open-label study. Melanoma Research, 21(1):80-83.
|PDF (Epub ahead of print version) - Registered users only|
|PDF (Verlags-PDF) - Registered users only|
The efficacy and tolerability of taurolidine, an antibacterial substance, was evaluated in a phase 2 trial enrolling patients with advanced melanoma. The treatment schedule consisted of daily taurolidine (20 g) administered intravenously for 5 days per week for 3 consecutive weeks followed by 1 week of rest. One cycle comprised of 28 days. A maximum of six cycles could be administered. Sixteen patients were assessable for tumor response, seven of whom had brain metastases. Three patients (18.8%) achieved disease stabilization, including a patient with a primary mucosal melanoma of the nasal cavity who had a marked locoregional response with disease stabilization of the distant metastases. Thirteen patients had disease progression. Median overall survival was 46±1 days. Adverse events were moderate and mainly gastrointestinal. Treatment with taurolidine has no activity in patients with advanced melanoma.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic|
|DDC:||610 Medicine & health|
|Deposited On:||05 Jan 2011 18:25|
|Last Modified:||27 Nov 2013 20:05|
|Publisher:||Lippincott Wiliams & Wilkins|
|Citations:||Web of Science®. Times cited: 1|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page